Navigation Links
Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
Date:7/15/2008

Most Up-to-Date Analysis of the Alzheimer's Disease Market Now Available

from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with Myriad Genetics/Lundbeck's decision to discontinue the development of Flurizan, the most likely first-to-market disease-modifying Alzheimer's disease treatment becomes Elan/Wyeth's bapineuzumab, an anti-beta-amyloid monoclonal antibody, expected to launch in 2011. The recent Phase III failure of Flurizan underscores the risk involved with developing an agent for Alzheimer's disease.

Decision Resources also finds that both bapineuzumab and Eli Lilly's LY-2062430 will quickly become blockbusters shortly after their launch due to their efficacy and high price point. The widespread use of these agents will depend, in part, on their safety and the complementary use of new diagnosis techniques that would permit patients to be diagnosed in the early stages of the disease, when disease-modifying therapies provide the greatest therapeutic benefit.

"We await Phase III results of the bapineuzumab trials with great interest, both in terms of the drug's safety profile, but also its efficacy in Alzheimer's disease patients carrying the ApoEe4 gene (which is a risk factor in Alzheimer's disease) compared with non-ApoEe4 gene carriers," states Andrea Witt, Ph.D., director at Decision Resources. "Should efficacy prove poor in ApoEe4 gene carriers, patients will be faced with the difficult decision of whether they would want to know whether they carry this gene. Nevertheless, even if bapineuzumab benefits only the non-ApoEe4 gene carriers-a prospective population of 40 to 70 percent of Alzheimer's disease patients-bapineuzumab stands to reap considerable profits in the Alzheimer's disease market."

Two new Decision Resources Alzheimer's disease reports-the Pharmacor report entitled Alzheimer's Disease and Brands & Strategies: Alzheimer's Disease-have been updated to include new data and analysis on how the Alzheimer's disease market is impacted by the failure of Flurizan. Some of the key questions answered in the reports include:

-- How does the failure of Flurizan impact the current Alzheimer's disease

market competitors, and which companies benefit the most?

-- How will the absence of Flurizan change the performance of emerging

therapies? Will the overall Alzheimer's disease market expand or

contract?

-- How will Lundbeck weather the failure of Flurizan?

-- What impact will Flurizan's discontinuation have on the Alzheimer's

disease market over the 2007-2017 time period?

-- Which drug stands most to gain from Flurizan's discontinuation?

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
3. Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
6. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
7. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
8. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
11. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):